Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Free Report) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Tvardi Therapeutics in a report issued on Monday, June 8th. HC Wainwright analyst S. Nik expects that the company will post earnings per share of ($0.78) for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($6.52) EPS and FY2028 earnings at ($6.86) EPS.
Several other research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. Finally, Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Tvardi Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $46.17.
Tvardi Therapeutics Stock Performance
Shares of TVRD stock opened at $2.78 on Wednesday. Tvardi Therapeutics has a 52 week low of $2.75 and a 52 week high of $43.65. The company has a market capitalization of $26.08 million, a price-to-earnings ratio of -0.90 and a beta of 0.33. The company has a 50-day simple moving average of $3.34 and a 200 day simple moving average of $3.77.
Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08).
Institutional Trading of Tvardi Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after buying an additional 20,757 shares during the period. American Financial Group Inc. acquired a new position in Tvardi Therapeutics in the 4th quarter valued at $962,000. Vestal Point Capital LP bought a new stake in shares of Tvardi Therapeutics during the 3rd quarter valued at $6,508,000. Geode Capital Management LLC grew its holdings in shares of Tvardi Therapeutics by 6.2% during the 4th quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock worth $676,000 after purchasing an additional 9,214 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Tvardi Therapeutics by 83.7% during the 4th quarter. State Street Corp now owns 115,501 shares of the company’s stock worth $497,000 after purchasing an additional 52,637 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.
Tvardi Therapeutics Company Profile
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Featured Articles
- Five stocks we like better than Tvardi Therapeutics
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
